Shares in several stem-cell firms rallied in the wake of a US appeals court decision to overturn an injunction that would freeze federal funding for research on human embryonic stem cells. After the 29 April ruling, StemCells, Advanced Cell Technology, Pluristem Therapeutics, Aastrom Biosciences and Geron all saw gains. See page 15 for more on the decision.
展开▼
